Multidisciplinary Care Ensures ‘Comfort’ in Decisions Surrounding Lumpectomy for Breast Cancer Subtype, Says Expert

Video

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota, details the multidisciplinary work that goes into delivering breast-conserving therapy for patients with multiple ipsilateral breast cancer.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with Judy C. Boughey, MD, a surgical oncologist of the Division of Breast and Melanoma Surgical Oncology and the Department of Surgery at Mayo Clinic in Rochester, Minnesota, about the collaborative, multidisciplinary considerations that go into breast-conserving therapy for patients with multiple ipsilateral breast cancer.

According to Boughey, patients receiving breast conservation therapy will get the full value of a multidisciplinary team including breast surgeons, radiation oncologists, and medical oncologists.

Transcript:

All of breast cancer care these days is very much multidisciplinary. For these patients with multiple ipsilateral breast cancer, it does bring the value of a multidisciplinary team’s input into that patient's care. If the patient chooses to proceed with breast-conserving therapy, that's going to involve not only surgical resection, but also the incorporation of adjuvant whole breast radiation.

We want to make sure that the patient and the radiation oncologists are comfortable proceeding with the radiation aspects, and then also to incorporate the medical oncologist in terms of the systemic therapy recommendations.

Reference

Boughey JC, Rosenkranz KM, Ballman KV, et al. Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – results from ACOSOG Z11102 (Alliance). Presented at the 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX; abstract GS4-01.

Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.
Related Content